Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsMinority InterestNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOther Accumulated ExpensesOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Bioventus (BVS) Receivables - Other (2020 - 2024)

Historic Receivables - Other for Bioventus (BVS) over the last 5 years, with Q4 2024 value amounting to $76000.0.

  • Bioventus' Receivables - Other fell 7042.8% to $76000.0 in Q4 2024 from the same period last year, while for Dec 2024 it was $76000.0, marking a year-over-year decrease of 7042.8%. This contributed to the annual value of $76000.0 for FY2024, which is 7042.8% down from last year.
  • Bioventus' Receivables - Other amounted to $76000.0 in Q4 2024, which was down 7042.8% from $6.5 million recorded in Q3 2024.
  • Over the past 5 years, Bioventus' Receivables - Other peaked at $50.0 million during Q4 2021, and registered a low of $76000.0 during Q4 2024.
  • Moreover, its 5-year median value for Receivables - Other was $257000.0 (2023), whereas its average is $8.2 million.
  • In the last 5 years, Bioventus' Receivables - Other surged by 22560.98% in 2022 and then crashed by 7042.8% in 2024.
  • Over the past 5 years, Bioventus' Receivables - Other (Quarter) stood at $81000.0 in 2020, then rose by 1.23% to $82000.0 in 2021, then surged by 225.61% to $267000.0 in 2022, then fell by 3.75% to $257000.0 in 2023, then plummeted by 70.43% to $76000.0 in 2024.
  • Its last three reported values are $76000.0 in Q4 2024, $6.5 million for Q3 2024, and $257000.0 during Q4 2023.